Related Experiment Video
Updated: Jul 9, 2026
08:11
Measuring Progressive Neurological Disability in a Mouse Model of Multiple Sclerosis
Published on: November 14, 2016
11.6K
What's new in multiple sclerosis?
Erika E Tillery1, Jennifer N Clements2, Zach Howard3
1Associate Professor of Pharmacy Practice, Presbyterian College School of Pharmacy, Clinton, South Carolina, etill2020@gmail.com.
The Mental Health Clinician
|June 30, 2018
Summary
New medications for relapsing-remitting multiple sclerosis (RRMS) offer comparable efficacy but varied safety profiles. Treatment selection for RRMS should consider patient preference, dosing, and potential adverse effects.
Area of Science:
- Neurology
- Pharmacology
Background:
- Multiple sclerosis (MS) is a chronic neurological disease with relapsing-remitting MS (RRMS) as the most common form.
- Recent years have seen an increase in approved treatments for RRMS.
Purpose of the Study:
- To provide an updated overview of medications approved for RRMS treatment since January 2010.
Main Methods:
- A literature review identified FDA-approved RRMS medications between January 2010 and April 2017.
- Package inserts and relevant articles were analyzed for key treatment information.
Main Results:
- Seven new medications for RRMS, including oral and injectable options, have been approved.
- All agents demonstrate comparable efficacy, with distinct safety profiles and potential adverse effects.
- Therapeutic choices depend on patient factors like preference, dosing, and safety.
Conclusions:
- Multiple treatment options are now available for RRMS.
- Optimal patient therapy requires careful consideration of adverse effects, administration route, and frequency.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:22Myasthenia Gravis ll: Pathophysiology
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...